Armata Pharmaceuticals, Inc. — Director's Dealing 2009

Jun 2, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2009-05-29

Reporting Person: DAVIE JOSEPH MD PHD (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-05-29	Stock option (right to buy)	$0.27	A	60000	Acquired	2019-05-29	Common Stock (60000)	Direct

Footnotes

F1: This option vests and becomes exercisable over a two-year period, as follows: 25% of the option shares vested and become exercisable on the date of grant, and the remaining 75% of the option shares will vest and become exercisable in two equal installments on the first and second anniversaries of the date of grant.